Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immune agent for controlling and curing I type diabetes mellitus

A technology of immunological preparations and diabetes, applied in the field of immunological preparations

Inactive Publication Date: 2010-01-20
GENERAL HOSPITAL OF PLA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, CD8 with tolerance function obtained in vitro + NK1.1 + NKT cells and CD8 + CD3 - T cells, and in vivo work for the control and treatment of type 1 diabetes have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune agent for controlling and curing I type diabetes mellitus
  • Immune agent for controlling and curing I type diabetes mellitus
  • Immune agent for controlling and curing I type diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1 prepares immune preparation SUP-NKT

[0039] 1 Materials and methods:

[0040] 1.1 Materials

[0041] C57BL / J mice (female, 18-20 g in weight, 6-8 weeks old): from the third-level animal room of the Experimental Animal Center of the PLA General Hospital;

[0042] RPMI1640 medium: purchased from Gibco;

[0043] MTT dye (tetramethylazolium salt 3-(4.5-dimethyliazol-zyl)-2.5-diphenyl tetrazoliumbromide): purchased from Sigma;

[0044] Dimethylsulfoxide (DMSO): purchased from Solarbio;

[0045] Fetal bovine serum: purchased from Veterinary Prevention and Control Center of Beijing Military Region;

[0046] SEB: prepared according to the method of Chinese patent ZL01103991.4;

[0047] Anti-CD3-PerCP, CD69-FITC, CD8-PE, NK1.1-APC fluorescent antibodies: all purchased from BD Company;

[0048] IL-2: purchased from Beijing Sihuan Biopharmaceutical Co., Ltd.

[0049] 1.2 Method

[0050] 1.2.1 Normal mouse lymphocyte preparation

[0051] Extract the splenocyt...

Embodiment 2

[0054] The active ingredient identification of embodiment 2 immune preparation SUP-NKT

[0055] Method: Analysis of SEB-activated SUP-NKT cell subsets

[0056] Add 1-10 × 10 in a 96-well plate 5 Cells (100 μl / well) were added with 0.1 mL SEB (200-400 μg / L), and cultured in a 37° C., 50 mL / L CO2 incubator. SUP-NKT cultured on days 10-30 were stained with anti-CD3-PerCP, CD69-FITC, CD8-PE and NK1.1-APC fluorescent antibodies, and the NKT cells were determined by flow cytometry (FACs Calibue BD, USA). The percentage of T cell subset proliferation and the differentiation pathway of the two cell subsets were recorded.

[0057] The results are shown in Table 1 and Table 2:

[0058] The main components of Table 1 SUP-NKT (n=4)

[0059]

[0060] t-test, ★★ P★ P<0.05 compared with C57BL / J group

[0061] Table 210-The composition of SUP-NKT within 30 days does not change (n=3~4)

[0062]

[0063] t-test, ★★ P<0.01, compared with C57BL / J group

[0064] The above results sh...

Embodiment 3

[0065] Example 3 Identification of SUP-NKT in vivo control and treatment of type 1 diabetes

[0066] Experimental animals and experimental methods: two mice with different MHC genetic backgrounds were selected for cell transplantation. The recipients were type I diabetes genetic mice NOD mice (female, raised in the experimental level 2 animal room), and the donors were SUP-NKT from C57BL / J mice. Use a blood glucose meter and a urine sugar meter to determine the outcome of the disease. Experimental animals were grouped as follows:

[0067] 1) NOD group (control group):

[0068] Ten NOD mice aged 3-5 weeks were intraperitoneally injected with normal saline and raised in a second-level animal room. They waited for the natural onset and recorded the incidence within 22 weeks.

[0069] Result: 100% disease, see figure 1 .

[0070] 2) SUP-NKT control group:

[0071] Inject 2 × 10 to 3-5 week old female NOD mice 9 -5×10 9 / L donor SUP-NKT cells, a total of 2 times. Incidence...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an immune agent which is obtained by amplifying staphylococcus aureus enterotoxin B in vitro. The agent essentially comprises CD8<+>NK1.1<+>NKT cell and CD8<+>CD3<-> T cell, and can be used for controlling and curing I type diabetes mellitus. The immune agent is proved that the cells are not reacted with classical antigen stimulators any longer, have lower limitation of major histocmpatible complex (MHC), and restrain the response reaction of normal lymphocyte to antigen, and can be used for anti rejection of organ transplantation. After being frozen and thawed, the immune agent has invariable functions.

Description

Technical field: [0001] The invention relates to an immune preparation prepared by staphylococcus aureus enterotoxin B. The present invention also relates to the application of the immune preparation in controlling and treating type I diabetes and in anti-rejection. Background technique: [0002] NKT cells are a unique group of cells in humans and mice, which were discovered in 1987 and named and defined in 1994. [0003] The recognized antigen capable of activating NKT cells is the glycolipid antigen α-galactosylceramid (α-GalCer). The functional NKT cell subset activated by the glycolipid antigen α-GalCer is mainly CD4 - CD8 - NKT and CD4 + NKT cells, in which CD4 + NKT cells play an important role in immune tolerance. [0004] Activated NKT cells have a variety of biological activities, such as mediating anti-infection and anti-tumor immunity, mediating anti-rejection in organ transplantation, and playing a role in tolerance regulation in autoimmune diseases to cont...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/26A61P3/10A61P37/06C12N5/06
Inventor 陈钰郭业磊
Owner GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com